(Sharecast News) - TheraCryf announced on Monday that it has entered into a master service agreement with contract research organisation Pharmaron UK to support the development of its Orexin-1 addiction treatment programme.
The AIM-traded firm said that under the agreement, Pharmaron would carry out the remaining preclinical work required to support...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE